Genome-wide association analysis of the human thalamus identifies novel genomic loci and reveals genetic overlap with distinct cortical regions and ten brain disorders

Competing Interest Statement

T.E. received speakers honoraria from Lundbeck and Janssen Cilag. O.A.A. is a consultant to HealthLytix and received speakers honorarium from Lundbeck.

Funding Statement

The authors were funded by the South-Eastern Norway Regional Health Authority 2015-078 (T.E.), 2013-123 (O.A.A.), 2014-097 (L.T.W.), 2015-073 (L.T.W.) and 2016-083 (L.T.W.), by the Research Council of Norway (276082 LifespanHealth (T.K.), 213837 (O.A.A), 223273 NORMENT (O.A.A.), 204966 (L.T.W.), 229129 (O.A.A.), 249795 (L.T.W.), 273345 (L.T.W.) and 283798 SYNSCHIZ (O.A.A.)), Stiftelsen Kristian Gerhard Jebsen, the European Research Council (ERCStG 802998 BRAINMINT (L.T.W.)), NVIDIA Corporation GPU Grant (T.K.), the Ebbe Froland foundation (T.E.), and a research grant from Mrs. Throne-Holst (T.E.). This research has been conducted using the UK Biobank Resource (access code 27412, https://www.ukbiobank.ac.uk/) and we would like to thank the research participants and employees of the UK Biobank. We also thank the ADHD, ASD, SCZ, BD, and MD Working Groups of the Psychiatric Genomics Consortium, the International Genomics of Alzheimer's Project, the International Multiple Sclerosis Genetics Consortium, International Parkinson Disease Genomics Consortium, The International League Against Epilepsy Consortium on Complex Epilepsies, and 23andMe, Inc. for granting us access to their GWAS summary statistics, and the many people who provided DNA samples for their studies. This work was performed on the TSD (Tjeneste for Sensitive Data) facilities, owned by the University of Oslo, operated and developed by the TSD service group at the University of Oslo, IT-Department (USIT) and on resources provided by UNINETT Sigma2 - the National Infrastructure for High Performance Computing and Data Storage in Norway.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The National Health Service National Research 411 Ethics Service (ref. 11/112 NW/0382) has approved the UK Biobank and all participants gave signed informed consent before study inclusion. The projects from which summary statistics of GWAS were used for genetic overlap analysis were each approved by the local ethics committees, and informed consent was obtained from all participants (these works are cited in the main text file). The Norwegian Regional Committees for Medical and Health Research Ethics (REC South East) evaluated our pipelines that use summary statistics from published works for genetic analysis as performed in the current study and found that no additional institutional approval is needed.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes